Oncology · Pancreatic CancerTrial Updateclinicalmid-term

Phase I Trial of Durvalumab and Olaparib with Radiation for Unresectable Pancreatic Cancer

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/29/2026, 6:30:35 PM

Assessment confidence: 75% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing phase I trial of durvalumab and olaparib combined with radiation therapy represents a significant advancement in the treatment of locally advanced unresectable pancreatic cancer. Success in this trial could reshape treatment protocols and enhance competitive positioning for companies involved in PARP inhibitors and immunotherapies. Regulatory context from FDA (FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer) supports the near-term read. Assessment grounded in 26 ranked evidence items (17 high-relevance).

Strategic Assessment

Success in this trial could validate the use of combination therapies in pancreatic cancer, influencing treatment protocols and competitive strategies for companies involved in these modalities. The strongest clinical anchor is Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial (ClinicalTrials.gov), entity match (national cancer institute). In Oncology · Pancreatic Cancer, 6 regulatory and 4 competitive items passed relevance filtering for Durvalumab.

Competitive Pressure

The most relevant competitive pressure comes from Sonesitatug vedotin shows significant survival benefit in advanced gastric cancers (Humanexa Signals) — sponsor/company relevance (astrazeneca); patient population match (advanced). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial.

Regulatory Outlook

Regulatory risk is concentrated around FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer (FDA). Patient population match (advanced). Positive trial outcomes may facilitate regulatory approvals for this combination therapy, impacting labeling and compliance requirements for the involved drugs.

Key Risks

Elevated medium regulatory exposure for Durvalumab could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Cancer Clinical Trial Eligibility Criteria: Laboratory Values) could weigh on Durvalumab through agency review timelines and labeling constraints if follow-through weakens.
Regulatory risk from FDA (Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications) could weigh on Durvalumab through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

If the trial demonstrates safety and efficacy, it could lead to increased adoption of these therapies, potentially boosting market share for involved companies in the oncology sector.
Upside for Durvalumab may improve if Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · ADC · Trial Update · This is the first Phase III trial to show an overall survival benefit with an anti-CLDN18.2 ADC, potentially positioning AstraZeneca favorably in the oncology market.
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for safety and efficacy, as well as subsequent developments in combination therapy approaches for pancreatic cancer.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer
FDAhigh relevance
Patient population match (advanced)
FDA document
View source
Verified Clinical Benefit | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Other | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Cancer Clinical Trial Eligibility Criteria: Laboratory Values
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
A Phase III Trial of Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
ClinicalTrials.govhigh relevance
Patient population match (unresectable)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Sonesitatug vedotin shows significant survival benefit in advanced gastric cancers
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca); Patient population match (advanced)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
NCI Trials B7-H3 CAR T Cell Therapy for Refractory Small Cell Lung Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment

Cost-effectiveness of ferumoxtran-enhanced macrophage-specific-MRI and PSMA-PET/CT versus ePLND for nodal staging in primary prostate cancer: a decision analysis based on updated phase-3 trial data.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Integrative single-cell and spatial transcriptomic approaches to decipher the tumor microenvironment and therapeutic resistance in pancreatic cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Durvalumab
Olaparib
National Cancer Institute

Commercial impact

medium

If the trial demonstrates safety and efficacy, it could lead to increased adoption of these therapies, potentially boosting market share for involved companies in the oncology sector.

Regulatory impact

medium

Positive trial outcomes may facilitate regulatory approvals for this combination therapy, impacting labeling and compliance requirements for the involved drugs.

What to watch

Monitor trial results for safety and efficacy, as well as subsequent developments in combination therapy approaches for pancreatic cancer.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.